Fog City Bio

Executive Summary

Fog City Bio is a specialized Contract Research Organization (CRO) headquartered in San Francisco, founded in 2020, that focuses on developing and optimizing advanced immunoassays for biotech and pharmaceutical clients. The company offers custom assay development, troubleshooting, and sample analysis services using ultra-sensitive and multiplex detection platforms. Its core mission is to deliver rigorously characterized, handoff-ready protocols to accelerate research in oncology, immunology, and other therapeutic areas. As a private company with no disclosed funding or valuation, Fog City Bio operates in the competitive CRO market, leveraging its expertise in assay development to support drug discovery and development programs. Given the increasing demand for precision medicine and biomarker-driven trials, Fog City Bio is well-positioned to capture market share by offering high-quality, customizable immunoassay solutions. The company's focus on ultra-sensitive and multiplex technologies aligns with industry trends toward more comprehensive and early-stage biomarker analysis. While specific financials are not available, the CRO sector continues to grow, and Fog City Bio's niche expertise may provide a competitive advantage. However, as a small private firm, it faces challenges in scaling operations and competing with larger CROs. Overall, the company represents a promising but early-stage opportunity in the life sciences tools space.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Ultra-Sensitive Multiplex Assay Platform70% success
• Q4 2026Strategic Partnership with Top 20 Pharma for Oncology Biomarker Assays60% success
• 2027Expansion into Gene Therapy and Cell Therapy Immunoassay Services50% success